Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 7M | 44M | 123M | 79M | 15M |
| Gross Profit | -150K | 16M | 71M | 33M | 5M |
| Operating Income | -39M | -22M | 24M | 10M | -4M |
| EBITDA | -32M | -15M | 29M | 11M | -1M |
| Net Income | -53M | -17M | 18M | 6M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.08
+0.00% today
1Y Change
-97.79%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ProPhase Labs, Inc. (PRPH) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.08 and down 97.8% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -84.7%, EPS growth of -166.3%, a dividend yield of 0.0%. What stands out right now is revenue -84.7%, EPS -166.3%, free cash flow -27.2% with operating margin -2496.6% and ROIC -156.9%. Valuation is more restrained than many high-expectation growth names at price/sales 0.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PRPH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRPH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PRPH Max Drawdown
-98.85%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PRPH and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$14.5M
-81.6% YoY
FY Net Income
-$2.1M
-133.9% YoY
Free Cash Flow
-$4.3M
+76.0% YoY
Revenue Growth
-84.7%
EPS Growth
-166.3%
Gross Margin
191.4%
Net Margin
-3872.2%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 7M | 44M | 123M | 79M | 15M |
| Gross Profit | -150K | 16M | 71M | 33M | 5M |
| Operating Income | -39M | -22M | 24M | 10M | -4M |
| EBITDA | -32M | -15M | 29M | 11M | -1M |
| Net Income | -53M | -17M | 18M | 6M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 678K | 2M | 9M | 9M | 7M |
| Total Assets | 63M | 92M | 88M | 89M | 31M |
| Total Liabilities | 56M | 43M | 24M | 31M | 21M |
| Shareholder Equity | 7M | 49M | 64M | 59M | 11M |
| Total Debt | 25M | 18M | 7M | 15M | 15M |
| Net Debt | 24M | 17M | -2M | 6M | 8M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
+81.0% YoY
Capital Expenditures
2M
+60.1% YoY
Free Cash Flow
4M
+76.0% YoY
Key ratios
Gross Margin
191.4%
Operating Margin
-2496.6%
Net Margin
-3872.2%
ROE
-404.4%
Debt / Equity
1.12x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.